Nexagon - Emerging Insights and Market Forecast - 2030

“Nexagon- Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Persistent Epithelial Defect in 7 Major Markets. A detailed picture of the Nexagon in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

Nexagon is a natural, unmodified oligonucleotide (30-mer) that downregulates expression of the key gap junction protein Cx43. Cx43 is upregulated and overexpressed in pathological conditions such as chemical or thermal injuries to the eye, resulting in non-healing of the crucial epithelial layer of the cornea. Nexagon is formulated in a thermoreversible gel placed under a contact lens or amniotic membrane to ensure contact with the corneal/conjunctival surface for sufficient time to get the active drug into the cell. Nexagon has received orphan drug designation by FDA.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Nexagon.
• The report contains forecasted sales for Nexagon till 2030.
• Comprehensive coverage of the mid-stage emerging therapies (Phase II) for Persistent Epithelial Defect.
• The report also features the SWOT analysis with analyst insights and key findings of Nexagon.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Nexagon Analytical Perspective

In-depth Nexagon Market Assessment

This report provides a detailed market assessment of Nexagon in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

Nexagon Clinical Assessment

The report provides the clinical trials information of Nexagon covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Persistent Epithelial Defect is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Nexagon dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Persistent Epithelial Defect are giving market competition to Nexagon and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of Nexagon.
• This in-depth analysis of the forecasted sales data of Nexagon from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Nexagon.

Key Questions Answered

• Which company is developing Nexagon along with the phase of the clinical study?
• What is the technology utilized in the development of Nexagon?
• What is the product type, route of administration and mechanism of action of Nexagon?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Nexagon development?
• What are the key designations that have been granted to Nexagon?
• What is the forecasted market scenario of Nexagon?
• What is the history of Nexagon and what is its future?
• What is the forecasted sales of Nexagon in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to Nexagon?
• Which are the late-stage emerging therapies under development for the treatment of the Persistent Epithelial Defect?